Biocon to launch new drug in July-Sept quarter
MUMBAI (Reuters) - Biocon(BION.NS), India's top listed biotech firm, plans to launch psoriasis drug Alzumab in the country in the July-September quarter, a top company executive said on Friday.
The company expects sales of 1 billion rupees from the drug over four years, Kiran Mazumdar-Shaw, chairman, Biocon said in a conference call.
Late on Thursday, Biocon reported an 8.24 percent rise in net profit to 920 million rupees for the Oct-Dec quarter compared with a year earlier.
(Reporting by Kaustubh Kulkarni; Editing by Prateek Chatterjee)
- Tweet this
- Share this
- Digg this
- India approves $2.6 bln mounted gun purchase - official
- 'Hunger Games' tops U.S. box office with $123 million opening
- Computer spying malware uncovered with 'stealth' features - Symantec
- Celebrity song to aid fight against Africa Ebola crisis tops UK charts
- Multi-national crew blasts off for space station
India approved on Saturday the purchase of 814 mounted gun systems for the army at a cost of 157.5 billion rupees ($2.55 billion), a defence ministry spokesman said. Full Article